- Home
- DAVE vs CDTX Comparison
DAVE vs CDTX Comparison
Compare DAVE & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVE
- CDTX
- Stock Information
- Founded
- DAVE 2017
- CDTX 2012
- Country
- DAVE United States
- CDTX United States
- Employees
- DAVE N/A
- CDTX N/A
- Industry
- DAVE Retail: Computer Software & Peripheral Equipment
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DAVE Technology
- CDTX Health Care
- Exchange
- DAVE Nasdaq
- CDTX Nasdaq
- Market Cap
- DAVE 3.2B
- CDTX 2.8B
- IPO Year
- DAVE N/A
- CDTX 2015
- Fundamental
- Price
- DAVE $251.02
- CDTX $94.34
- Analyst Decision
- DAVE Strong Buy
- CDTX Strong Buy
- Analyst Count
- DAVE 6
- CDTX 13
- Target Price
- DAVE $265.50
- CDTX $118.50
- AVG Volume (30 Days)
- DAVE 388.4K
- CDTX 1.0M
- Earning Date
- DAVE 11-04-2025
- CDTX 11-06-2025
- Dividend Yield
- DAVE N/A
- CDTX N/A
- EPS Growth
- DAVE 70.95
- CDTX N/A
- EPS
- DAVE 3.84
- CDTX N/A
- Revenue
- DAVE $433,065,000.00
- CDTX N/A
- Revenue This Year
- DAVE $50.28
- CDTX N/A
- Revenue Next Year
- DAVE $15.34
- CDTX N/A
- P/E Ratio
- DAVE $64.70
- CDTX N/A
- Revenue Growth
- DAVE 47.97
- CDTX N/A
- 52 Week Low
- DAVE $37.44
- CDTX $11.12
- 52 Week High
- DAVE $286.45
- CDTX $121.21
- Technical
- Relative Strength Index (RSI)
- DAVE 65.95
- CDTX 49.37
- Support Level
- DAVE $208.60
- CDTX $97.85
- Resistance Level
- DAVE $224.68
- CDTX $104.77
- Average True Range (ATR)
- DAVE 15.01
- CDTX 6.30
- MACD
- DAVE 4.28
- CDTX -2.50
- Stochastic Oscillator
- DAVE 92.59
- CDTX 1.56
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.